Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022
Addiction · 2024
DOI: 10.1111/add.16652 ↗At a glance
Journal article in Addiction, 2024. Written by Rachael K Ross and 2 co-authors. Institution: Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. Major MEDLINE topics: Medicaid, Buprenorphine, Delayed-Action Preparations, Opioid-Related Disorders. Cited 7 times so far (Crossref); 24 references. The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, National Institute on Drug Abuse of the National Institutes of Health, National Institute on Drug Abuse.
Abstract (original language)
Background and aims Extended release buprenorphine injection (INJ‐BUP) has been available in the United States since 2018. INJ‐BUP has the potential to positively impact opioid use disorder (OUD) treatment outcomes by providing additional treatment options. As one of the largest payers of OUD treatment in the US, Medicaid coverage is important for access and uptake of INJ‐BUP. Uptake of INJ‐BUP among Medicaid beneficiaries has not been described since 2019 and variation in uptake by state has not previously been explored. We aimed to measure prescribing of INJ‐BUP for Medicaid beneficiaries since 2018, nationwide and by state.
Methods
We analyzed State Drug Utilization Data from 2017 to 2022 and calculated the number of prescription fills for INJ‐BUP and oral buprenorphine paid by Medicaid. To compare across states, we calculated the number of prescription fills per 100 Medicaid beneficiaries treated for OUD using data from Transformed Medicaid Statistical Information System Substance Use Disorder (T‐MSIS SUD) Data Books. Data sources are publicly available.
Results
The number of prescription fills for INJ‐BUP paid by Medicaid increased from 4322 (0.1% of all buprenorphine prescription fills) in 2018 to 186 861 (2.0%) in 2022. Each year the increase in fills exceeded the prior year change, indicating accelerating uptake. There was notable variability across states.
Conclusions
The number of extended release buprenorphine injection prescriptions among US Medicaid beneficiaries treated for opioid use disorder increased from over 4000 prescriptions in 2018 to over 185 000 in 2022 but uptake is much less than observed in other countries over shorter time periods.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
- Division of General Internal Medicine and Health Services Research, School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
ORCID profiles: Rachael K Ross, Kara E Rudolph, Chelsea L Shover
Funding
- NIDA NIH HHS
- National Institute on Drug Abuse of the National Institutes of Health
- National Institute on Drug Abuse
Cite
APA
Ross, R. K., Rudolph, K. E., & Shover, C. L. (2024). Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022. Addiction. https://doi.org/10.1111/add.16652
Vancouver
Ross RK, Rudolph KE, Shover CL. Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022. Addiction. 2024. doi:10.1111/add.16652
BibTeX
@article{Ross2024,
author = {Ross, Rachael K and Rudolph, Kara E and Shover, Chelsea L},
title = {Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022},
journal = {Addiction},
year = {2024},
doi = {10.1111/add.16652}
}
EUVIMED